New Findings on Atuzaginstat's Impact on Neuropsychiatric Symptoms in Alzheimer's Disease Presented at AAIC 2026

Lighthouse Pharmaceuticals Presents New Findings at AAIC 2026

Introduction
At the Alzheimer's Association International Conference (AAIC) 2026, Lighthouse Pharmaceuticals unveiled promising results from its Phase 2/3 GAIN trial. The focus of this trial was on Atuzaginstat, a novel gingipain inhibitor specifically targeting the bacterium Porphyromonas gingivalis (Pg). The data presented indicates significant benefits in dealing with neuropsychiatric symptoms which are prevalent among Pg-positive Alzheimer’s patients.

Phase 2/3 GAIN Trial Insights
The findings from this extensive trial are monumental. In a subgroup of Alzheimer’s patients identified as Pg-positive, Atuzaginstat was shown to slow cognitive decline by a significant 57% (p=0.02) on the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog11). Additionally, new analysis from the Neuropsychiatric Inventory (NPI) illustrated noteworthy reductions in symptoms such as agitation, aggression, disinhibition, elation, and apathy. These improvements were documented after 48 weeks of treatment when compared to those receiving a placebo.

Significance of Results
Perhaps more compelling is the correlating decrease in caregiver distress observed. This finding underscores the dual benefit of Atuzaginstat, not only improving the quality of life for Alzheimer’s patients, but also alleviating the burden faced by caregivers. Interestingly, no significant benefits were reported among Pg-negative patients regarding neuropsychiatric symptoms, marking a clear distinction in treatment effects based on Pg status.

Expert Commentary
Dr. Michael Detke, Chief Medical Officer of Lighthouse Pharmaceuticals, expressed the importance of these findings. He remarked, "Agitation and other behavioral symptoms are among the most challenging aspects of Alzheimer's disease for patients and caregivers, yet no disease-modifying treatments exist. These findings suggest that targeting gingipains may provide benefits beyond cognition in Pg-positive Alzheimer's disease, in reducing and preventing the emergence of neuropsychiatric symptoms." Dr. Detke’s comments reflect a hopeful perspective that could change treatment paradigms in Alzheimer’s care.

Future Directions and Ongoing Trials
Lighthouse Pharmaceuticals is advancing to the next stage with LHP588, a next-generation gingipain inhibitor with favorable Phase 1 safety outcomes. Currently, the Phase 2 SPRING trial is enrolled with around 300 Pg-positive Alzheimer’s patients. This study’s expansive design evaluates not just cognitive functions but also agitation, aggression, and overall patient functionality, demonstrating Lighthouse’s comprehensive approach to Alzheimer’s treatment.

The SPRING trial is set to engage participants across the United States, putting the spotlight on a crucial area of Alzheimer’s research and offering hope to families affected by this challenging condition. Detailed information on participant enrollment is accessible at their official website, www.springclinicaltrial.com.

Poster Presentation Details
Lighthouse's data will be featured in a poster session at AAIC on July 13, 2026, running from 7:30 a.m. to 4:30 p.m. Interested parties can find further details, including presentation abstracts online at Lighthouse Pharmaceuticals’ publication page.

About Lighthouse Pharmaceuticals
As a clinical-stage biopharmaceutical company, Lighthouse Pharmaceuticals is dedicated to developing innovative small-molecule therapies aimed at chronic neurodegenerative and inflammatory diseases. Its leading product, LHP588, is currently being investigated in NIH-funded trials aimed at combating Alzheimer’s disease. More information on the company and its research initiatives can be found at www.lighthousepharma.com.

Lighthouse’s endeavors are supported by the National Institute on Aging of the National Institutes of Health, with funding from Award Number R01AG088524. The views expressed in the findings do not inherently reflect those of the NIH, ensuring that Lighthouse maintains its commitment to scientific integrity and impactful healthcare solutions.